Skip to main content

In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo.

Publication ,  Journal Article
Pisetsky, DS
Published in: Annals of internal medicine
July 2024

Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. 38364841.

Duke Scholars

Published In

Annals of internal medicine

DOI

EISSN

1539-3704

ISSN

0003-4819

Publication Date

July 2024

Volume

177

Issue

7

Start / End Page

JC79

Related Subject Headings

  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Multicenter Studies as Topic
  • Middle Aged
  • Male
  • Inflammation
  • Humans
  • General & Internal Medicine
  • Female
  • Double-Blind Method
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pisetsky, D. S. (2024). In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo. Annals of Internal Medicine, 177(7), JC79. https://doi.org/10.7326/annals-24-00740-jc
Pisetsky, David S. “In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo.Annals of Internal Medicine 177, no. 7 (July 2024): JC79. https://doi.org/10.7326/annals-24-00740-jc.
Pisetsky DS. In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo. Annals of internal medicine. 2024 Jul;177(7):JC79.
Pisetsky, David S. “In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo.Annals of Internal Medicine, vol. 177, no. 7, July 2024, p. JC79. Epmc, doi:10.7326/annals-24-00740-jc.
Pisetsky DS. In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo. Annals of internal medicine. 2024 Jul;177(7):JC79.

Published In

Annals of internal medicine

DOI

EISSN

1539-3704

ISSN

0003-4819

Publication Date

July 2024

Volume

177

Issue

7

Start / End Page

JC79

Related Subject Headings

  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Multicenter Studies as Topic
  • Middle Aged
  • Male
  • Inflammation
  • Humans
  • General & Internal Medicine
  • Female
  • Double-Blind Method